What is Azitra?
Azitra, Inc., headquartered in Branford, Connecticut, is at the forefront of developing precision dermatological therapies. Established in 2014, the company employs advanced scientific methodologies, including genetic engineering, proteomics, and microbiome research, to create targeted treatments for conditions such as Netherton syndrome and EGFR inhibitor-associated rash. Azitra's proprietary platform integrates a vast microbial library with AI and machine learning to identify and advance novel therapeutic candidates, particularly focusing on engineered proteins and live biotherapeutic products derived from Staphylococcus epidermidis. The company's strategic approach to the skin microbiome aims to deliver highly personalized and effective dermatological solutions.
How much funding has Azitra raised?
Azitra has raised a total of $33.3M across 4 funding rounds:
Debt
$2.1M
Series A
$14M
Debt
$150K
Series B
$17M
Debt (2018): $2.2M with participation from Bios Partners and Connecticut Innovations
Series A (2019): $14M led by Godfrey Capital, KdT Ventures, Connecticut Innovations, and Bios Partners
Debt (2020): $150K supported by PPP
Series B (2020): $17M featuring Bios Partners, Connecticut Innovations, and Leaps by Bayer
Key Investors in Azitra
Bios Partners
Bios Partners is a venture capital firm dedicated to advancing biotech innovations, with a strategic focus on identifying and supporting compelling scientific opportunities, particularly in the Central U.S. They invest in clinical-stage companies developing novel therapeutics.
Connecticut Innovations
Connecticut Innovations (ctinnovations.com) serves as Connecticut's strategic venture capital arm, providing crucial equity and debt financing, along with strategic guidance, to foster the growth of innovative companies within the state, with a particular emphasis on biosciences.
KdT Ventures
KdT Ventures is a venture capital firm specializing in early-stage frontier science investments, focusing on transformative technologies in medicine, chemicals, and materials. They are known for leading pre-seed and seed funding rounds for innovative companies.
What's next for Azitra?
With the recent influx of major strategic investment, Azitra is poised to further its mission of addressing unmet medical needs in dermatology. The company's focus on developing next-generation therapies, supported by its robust platform and ongoing clinical trials, positions it for significant growth. Future endeavors will likely involve expanding its pipeline, advancing current drug candidates through regulatory pathways, and potentially forging new strategic collaborations to enhance its market reach and therapeutic impact. The substantial capital infusion signals a critical phase of scaling and commercialization for Azitra's innovative treatments.
See full Azitra company page
